Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

Also called NCT04927949

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 128 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04927949
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04927949. Randomized; no masking; primary purpose treatment. Start 2021-06-08 (actual); primary completion 2023-03-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
Acronym
ERMIT
Condition
ST-elevation Myocardial Infarction
Intervention (Drug)
cangrelor perfusion during PCI (percutaneous coronary intervention)
Intervention (Procedure)
standard PCI
Lead sponsor
University Hospital, Caen (class: other)
Collaborator
Terumo Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct04927949
Content hash
d95ebb77747205ff195c97dc01a9f14e701f2417c79594b01cf521a3aca34f4c